GC-MS Analysis, Antibacterial, and Anticancer Activities of Hibiscus sabdariffa L. Methanolic Extract: In Vitro and In Silico Studies
- PMID: 37375103
- PMCID: PMC10302641
- DOI: 10.3390/microorganisms11061601
GC-MS Analysis, Antibacterial, and Anticancer Activities of Hibiscus sabdariffa L. Methanolic Extract: In Vitro and In Silico Studies
Abstract
The emergence of bacteria that are resistant to several antibiotics has represented a serious hazard to human health globally. Bioactive metabolites from medicinal plants have a wide spectrum of therapeutic possibilities against resistant bacteria. Therefore, this study was performed to investigate the antibacterial efficacy of various extracts of three medicinal plants as Salvia officinalis L., Ziziphus spina-christi L., and Hibiscus sabdariffa L. against pathogenic Gram-negative Enterobacter cloacae (ATCC13047), Pseudomonas aeruginosa (RCMB008001), Escherichia coli (RCMB004001), and Gram-positive Staphylococcus aureus (ATCC 25923), bacteria using the agar-well diffusion method. Results revealed that, out of the three examined plant extracts, the methanol extract of H. sabdariffa L. was the most effective against all tested bacteria. The highest growth inhibition (39.6 ± 0.20 mm) was recorded against E. coli. Additionally, the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of the methanol extract of H. sabdariffa were detected in the case of all tested bacteria. Moreover, an antibiotic susceptibility test revealed that all tested bacteria showed multidrug resistance (MDR). While 50% of tested bacteria were sensitive and 50% were intermediately sensitive to piperacillin/tazobactam (TZP) based on the inhibition zone but still less than the extract. Synergistic assay demonstrated the promising role of using a combination of H. sabdariffa L. and (TZP) against tested bacteria. A surface investigation using a scanning electron microscope of the E. coli treated with TZP, extract, or a combination of the two revealed extremely considerable bacterial cell death. In addition, H. sabdariffa L. has a promising anticancer role versus Caco-2 cells with IC50 of 17.51 ± 0.07 µg/mL and minimal cytotoxicity upon testing versus Vero cells with CC50 of 165.24 ± 0.89 µg/mL. Flow cytometric analysis confirmed that H. sabdariffa extract significantly increased the apoptotic rate of Caco-2-treated cells compared to the untreated group. Furthermore, GC-MS analysis confirmed the existence of various bioactive components in the methanol hibiscus extract. Utilizing molecular docking with the MOE-Dock tool, binding interactions between n-Hexadecanoic acid, hexadecanoic acid-methyl ester, and oleic acid, 3-hydroxypropyl ester were evaluated against the target crystal structures of E. coli (MenB) (PDB ID:3T88) and the structure of cyclophilin of a colon cancer cell line (PDB ID: 2HQ6). The observed results provide insight into how molecular modeling methods might inhibit the tested substances, which may have applications in the treatment of E. coli and colon cancer. Thus, H. sabdariffa methanol extract is a promising candidate to be further investigated for developing alternative natural therapies for infection treatment.
Keywords: GC-MC; MDR; antibacterial; anticancer; docking study; medicinal plants; scanning electron microscope.
Conflict of interest statement
The authors declare no conflict of interest.
Figures










Similar articles
-
Phytochemical and antibacterial properties of calyces Hibiscus sabdariffa L.: an in vitro and in silico multitarget-mediated antibacterial study.BMC Complement Med Ther. 2025 Feb 18;25(1):62. doi: 10.1186/s12906-025-04794-1. BMC Complement Med Ther. 2025. PMID: 39966872 Free PMC article.
-
Antibacterial efficiency of the Sudanese Roselle (Hibiscus sabdariffa L.), a famous beverage from Sudanese folk medicine.J Intercult Ethnopharmacol. 2016 Mar 24;5(2):186-90. doi: 10.5455/jice.20160320022623. eCollection 2016 Mar-Apr. J Intercult Ethnopharmacol. 2016. PMID: 27104041 Free PMC article.
-
Antibacterial Activity of Hibiscus sabdariffa (Rosella) Using Methanolic Extract.J Pharm Bioallied Sci. 2024 Apr;16(Suppl 2):S1191-S1194. doi: 10.4103/jpbs.jpbs_527_23. Epub 2024 Apr 16. J Pharm Bioallied Sci. 2024. PMID: 38882855 Free PMC article.
-
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.Drugs. 2022 Apr;82(5):533-557. doi: 10.1007/s40265-022-01688-1. Epub 2022 Mar 16. Drugs. 2022. PMID: 35294769 Review.
-
A Comprehensive Review of the Antimicrobial Effects of Hibiscus Species.Cureus. 2024 Nov 5;16(11):e73062. doi: 10.7759/cureus.73062. eCollection 2024 Nov. Cureus. 2024. PMID: 39640147 Free PMC article. Review.
Cited by
-
Novel Disperse Dyes Based on Enaminones: Synthesis, Dyeing Performance on Polyester Fabrics, and Potential Biological Activities.Molecules. 2024 May 9;29(10):2227. doi: 10.3390/molecules29102227. Molecules. 2024. PMID: 38792089 Free PMC article.
-
Antibacterial activity of green synthesized copper oxide nanoparticles against multidrug-resistant bacteria.Sci Rep. 2024 Oct 23;14(1):25020. doi: 10.1038/s41598-024-75147-0. Sci Rep. 2024. PMID: 39443504 Free PMC article.
-
Phytochemical and antibacterial properties of calyces Hibiscus sabdariffa L.: an in vitro and in silico multitarget-mediated antibacterial study.BMC Complement Med Ther. 2025 Feb 18;25(1):62. doi: 10.1186/s12906-025-04794-1. BMC Complement Med Ther. 2025. PMID: 39966872 Free PMC article.
-
Pioneering study of Egyptian Neem and Jojoba extracts with molecular docking combat hospital multidrug resistant bacteria.Braz J Microbiol. 2025 Mar;56(1):425-445. doi: 10.1007/s42770-024-01590-w. Epub 2025 Jan 8. Braz J Microbiol. 2025. PMID: 39775688
-
Discovery of Novel Thiazole-Based SIRT2 Inhibitors as Anticancer Agents: Molecular Modeling, Chemical Synthesis and Biological Assays.Int J Mol Sci. 2024 Oct 15;25(20):11084. doi: 10.3390/ijms252011084. Int J Mol Sci. 2024. PMID: 39456864 Free PMC article.
References
-
- Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., Monnet D.L. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012;18:268–281. doi: 10.1111/j.1469-0691.2011.03570.x. - DOI - PubMed
-
- Shamsuzzaman S.M. Multidrug-resistant, extensively drug-resistant and Pandrug-resistant bacteria and antimicrobial therapy in combination. Bangladesh J. Med. Microbiol. 2015;9:1–2. doi: 10.3329/bjmm.v9i2.31348. - DOI
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous